CRISPR-Cas9 has become a central genome-editing platform in molecular biotechnology, enabling sequence-specific DNA editing in a highly efficient and relatively simple manner. Its use has greatly improved functional genomics because it enables the knockout, insertion, and correction of specific genes to speed up disease modeling and target validation. CRISPR-based approaches are being explored in translational studies in the treatment of monogenic disorders, oncology, and immunotherapy, as well as engineered T-cell methods. Continued studies have been done to enhance editing fidelity, reducing off-target effects, and to construct future CRISPR systems that would be very important in the future of precision therapeutics.
https://www.nature.com/articles/s41392-023-01309-7
MBH/AB